

**PRINTER RUSH**  
(PTO ASSISTANCE)

Application : <u>09/542,520</u>	Examiner : <u>Kunz</u>	GAU : <u>1647</u>
From: <u>NPB</u>	Location: <u>IDC</u> FMF FDC	Date: <u>11/10/04</u>

IFWLE)

Tracking #: 05936713

Week Date: 4/19/04

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input checked="" type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input checked="" type="checkbox"/> Other <u>drawing sheets</u>
<input type="checkbox"/> DRW	_____	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input type="checkbox"/> SPEC	_____	

**[RUSH] MESSAGE:**

① please verify relationship of continuing data Serial NO. 08/942,596  
bib sheet shows "CONTINUATION", text reads "CONTINUATION IN-PART"  
(Palm cannot be updated - error message) - see attached.

[REDACTED]

[REDACTED]

[REDACTED]

*Thank you*

**[XRUSH] RESPONSE:**

**INITIALS:**

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04



## UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY

 COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov


Bib Data Sheet

<b>SERIAL NUMBER</b> 09/542,520	<b>FILING DATE</b> 04/03/2000 <b>RULE</b> -	<b>CLASS</b> 530	<b>GROUP ART UNIT</b> 1646	<b>ATTORNEY DOCKET NO.</b> 7969-076-999
<b>APPLICANTS</b> W. James Jackson, Marriottsville, MD ; John L. Pace, Germantown, MD ;				
<b>** CONTINUING DATA *****</b> THIS APPLICATION IS A CON OF PCT/US98/20737 10/01/1998 WHICH IS A CON OF 08/942,596 10/02/1997 <i>10-16-02</i>				
<b>** FOREIGN APPLICATIONS *****</b> <i>none</i>				
<b>IF REQUIRED, FOREIGN FILING LICENSE</b> <b>GRANTED ** 06/16/2000</b>				
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after met <input type="checkbox"/> Allowance <i>SAW</i> Verified and Acknowledged <input type="checkbox"/> Examiner's Signature Initials		<b>STATE OR COUNTRY</b> MD	<b>SHEETS DRAWING</b> 11	<b>TOTAL CLAIMS</b> 61
<b>INDEPENDENT CLAIMS</b> 6				
<b>ADDRESS</b>  20583				
<b>TITLE</b> Chlamydia protein, gene sequence and uses thereof				
<b>FILING FEE RECEIVED</b> 2160	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	

B1 This application is a continuation of PCT/US98/20737 filed October 1, 1998 which is a continuation-in-part of U.S. Patent Application No. 08/942,596 filed October 2, 1997.

**IN THE CLAIMS:**

Please cancel non-elected claims 1, 20, 23-31 and 38-41 without prejudice.

Please amend 21, 32, 33, 35-37 to read as set forth below:

B1' 21. (Once Amended) A method of producing an immune response in an animal comprising administering to said animal an effective amount of an antigenic composition comprising an isolated *Chlamydia* species high molecular weight (HMW) protein wherein the apparent molecular weight is about 105-115 kDa, as determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE), wherein the *Chlamydia* species is *Chlamydia trachomatis*, *Chlamydia pecorum*, or *Chlamydia pneumoniae*, or an analogue of the HMW protein wherein the analogue has an apparent molecular weight of about 105-115 kDa, as determined by SDS-PAGE and is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16.

B2 32. (Once Amended) A method of preventing, treating or ameliorating a disorder related to *Chlamydia* in a host in need thereof comprising administering to a host, an effective amount of a pharmaceutical composition or vaccine composition comprising an isolated *Chlamydia* species high molecular weight (HMW) protein wherein the apparent molecular weight is about 105-115 kDa, as determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE), wherein the *Chlamydia* species is *Chlamydia trachomatis*, *Chlamydia pecorum*, or *Chlamydia pneumoniae*, or an analogue of the HMW protein wherein the analogue has an apparent molecular weight of about 105-115 kDa, as determined by SDS-PAGE and is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16 or a fragment of said HMW wherein the fragment is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16 or a recombinant protein comprising a *Chlamydia* protein and a leader sequence, wherein the apparent